Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

P C Contreras

Showing results (41-50 of 62) with videos related to

Pageof 7
Sort By:
Neuropharmacology|December 1, 1990
Neurochemical characterization of dopaminergic effects of opipramol, a potent sigma receptor ligand, in vivoT S Rao, J A Cler, S J Mick, et al.
Brain Research|July 9, 1990
Inhibition of potassium-evoked release of cholecystokinin from rat caudate-putamen, cerebral cortex and hippocampus incubated in vitro by phencyclidine and related compoundsL R Allard, J S Brog, J C Viereck, et al.
Experimental Neurology|November 1, 1993
Insulin-like growth factor-I: potential for treatment of motor neuronal disordersM E Lewis, N T Neff, P C Contreras, et al.
The Journal of Comparative Neurology|August 26, 1998
Immunolocalization of the mitogen-activated protein kinases p42MAPK and JNK1, and their regulatory kinases MEK1 and MEK4, in adult rat central nervous systemD G Flood, J P Finn, K M Walton, et al.
Synapse (New York, N.Y.)|January 1, 1987
PCP-induced alterations in cerebral glucose utilization in rat brain: blockade by metaphit, a PCP-receptor-acylating agentC A Tamminga, K Tanimoto, S Kuo, et al.
Annals of the New York Academy of Sciences|August 27, 1993
The potential of insulin-like growth factor-I as a therapeutic for the treatment of neuromuscular disordersM E Lewis, J L Vaught, N T Neff, et al.
Neuropharmacology|December 1, 1990
Opipramol, a potent sigma ligand, is an anti-ischemic agent: neurochemical evidence for an interaction with the N-methyl-D-aspartate receptor complex in vivo by cerebellar cGMP measurementsT S Rao, J A Cler, S J Mick, et al.
Peptides|September 1, 1984
Evidence for an endogenous peptide ligand for the phencyclidine receptorR Quirion, D A DiMaggio, E D French, et al.
Journal of Neurochemistry|March 1, 1991
Contrasting neurochemical interactions of tiletamine, a potent phencyclidine (PCP) receptor ligand, with the N-methyl-D-aspartate-coupled and -uncoupled PCP recognition sitesT S Rao, P C Contreras, J A Cler, et al.
Journal of Neurochemistry|March 11, 1991
Neurochemical interactions of competitive N-methyl-D-aspartate antagonists with dopaminergic neurotransmission and the cerebellar cyclic GMP system: functional evidence for a phasic glutamatergic control of the nigrostriatal dopaminergic pathwayT S Rao, J A Cler, S J Mick, et al.
Pageof 7

Showing results (41-50 of 62) with videos related to

Sort By:
Pageof 7
Neuropharmacology|December 1, 1990
Neurochemical characterization of dopaminergic effects of opipramol, a potent sigma receptor ligand, in vivoT S Rao, J A Cler, S J Mick, et al.
Brain Research|July 9, 1990
Inhibition of potassium-evoked release of cholecystokinin from rat caudate-putamen, cerebral cortex and hippocampus incubated in vitro by phencyclidine and related compoundsL R Allard, J S Brog, J C Viereck, et al.
Experimental Neurology|November 1, 1993
Insulin-like growth factor-I: potential for treatment of motor neuronal disordersM E Lewis, N T Neff, P C Contreras, et al.
The Journal of Comparative Neurology|August 26, 1998
Immunolocalization of the mitogen-activated protein kinases p42MAPK and JNK1, and their regulatory kinases MEK1 and MEK4, in adult rat central nervous systemD G Flood, J P Finn, K M Walton, et al.
Synapse (New York, N.Y.)|January 1, 1987
PCP-induced alterations in cerebral glucose utilization in rat brain: blockade by metaphit, a PCP-receptor-acylating agentC A Tamminga, K Tanimoto, S Kuo, et al.
Annals of the New York Academy of Sciences|August 27, 1993
The potential of insulin-like growth factor-I as a therapeutic for the treatment of neuromuscular disordersM E Lewis, J L Vaught, N T Neff, et al.
Neuropharmacology|December 1, 1990
Opipramol, a potent sigma ligand, is an anti-ischemic agent: neurochemical evidence for an interaction with the N-methyl-D-aspartate receptor complex in vivo by cerebellar cGMP measurementsT S Rao, J A Cler, S J Mick, et al.
Peptides|September 1, 1984
Evidence for an endogenous peptide ligand for the phencyclidine receptorR Quirion, D A DiMaggio, E D French, et al.
Journal of Neurochemistry|March 1, 1991
Contrasting neurochemical interactions of tiletamine, a potent phencyclidine (PCP) receptor ligand, with the N-methyl-D-aspartate-coupled and -uncoupled PCP recognition sitesT S Rao, P C Contreras, J A Cler, et al.
Journal of Neurochemistry|March 11, 1991
Neurochemical interactions of competitive N-methyl-D-aspartate antagonists with dopaminergic neurotransmission and the cerebellar cyclic GMP system: functional evidence for a phasic glutamatergic control of the nigrostriatal dopaminergic pathwayT S Rao, J A Cler, S J Mick, et al.
Pageof 7